close

Fundraisings and IPOs

1 59 60 61 62 63 74
Number of results: 1471
Date Company Amount Funding type Investors Therapeutic area Type of Information
2012-09-11 Arsanis Biosciences (Austria) €1.54 million grant Austrian Research Promotion Agency (Austria) Infectious diseases Grant
2012-09-11 Arsanis Biosciences (Austria) € 4.55 million grant Austrian Research Promotion Agency (Austria) - European Eurostars Programme (EU) Infectious diseases Grant
2012-09-07 Biotie Therapies (Finland) € 30 million private placement Lundbeck (Denmark) Neurodegenerative diseases - Mental diseases Private placement
2012-09-06 Karus Therapeutics (UK) $7.6 million series B financing round SV Life Sciences (UK-USA)
New Leaf Ventures (USA)
Novo A/S (Denmark)
International Biotechnology Trust (UK)
IP Group (UK)
a number of Angel investors
Cancer - Oncology - Inflammatory diseases Fundraising
2012-09-05 F2G (UK) $30 Million (€ 23.75 million) financing round Advent Life Sciences
Novartis Bioventures (Switzerland)
Sunstone Capital
Merifin Capital
K Nominees
Astellas Venture Fund
Infectious diseases Fundraising
2012-09-04 Theravectys (France) € 7.48 million fundraising private investors including
Guy Paillaud former executive manager of Promodes
John Pieters, former CEO of Amgen France
some of the company's historical investors
and 10 new private investors, which include the Tethys fund (Bettenfourt family), Philippe Oddo and Richard Hennessy.
Infectious diseases Fundraising
2012-09-04 Laurantis Pharma (Finland) € 5.64 million Broadview Ventures (USA) - Inveni Capital - Aloitusrahasto Vera - Helsinki University Funds (Finland) - Veritas Immunological diseases - Inflammatory diseases Fundraising
2012-09-03 to-BBB technologies (The Netherlands) € 1.25 million grant Ophtalmalogical diseases - Genetic diseases - Rare diseases Grant
2012-08-24 Wilex (Germany) € 23.9 million private placement UCB Pharma (Belgium) - dievini Hopp BioTech (Germany)  - other existing shareholders Cancer - Oncology Private placement
2012-08-03 Biotie Therapies (Finland) up to € 20 million standby equity Yorkville Advisors LLC (USA) Neurodegenerative diseases - Psychiatric diseases Fundraising
2012-08-03 Genfit (France) €2 million bond loan Cardiovascular diseases - Metabolic diseases - Liver diseases Fundraising
2012-08-02 Summit (UK) up to £150,000 grant Technology Strategy Board (UK) Neurodegenerative diseases Grant
2012-08-01 Pharming (The Netherlands) up to €10 Million equity working capital facility Kingsbrook Opportunities Master Fund LP - other institutional investors Rare diseases - Genetic diseases Fundraising
2012-07-31 Silence Therapeutics (UK) £5.45 million fundraising through the issue of new ordinary shares Private placement
2012-07-30 Vaccibody (Norway) 875 000 € share issue The Norwegian Radium Hospital Research Foundation (Norway) - Sarsia Seed (Norway) - additional 9 investors Infectious diseases Fundraising
2012-07-24 Oxford Gene Technology (UK) €3 million grant Infectious diseases Grant
2012-07-23 Cell Medica (UK) £24 million (€30.8 million) financing round Imperial Innovations (UK)
Invesco Perpetual (UK)
the Cancer Prevention and Research Institute of Texas (CPRIT) (USA)
Cancer - Oncology - Infectious diseases - Transplantation Fundraising
2012-07-23 Oxford BioMedica (UK) $125,000 (€103 310) award the Foundation Fighting Blindness (FFB) (USA) Ophtalmological diseases - Rare diseases - Genetic diseases Subvention
2012-07-17 Domain Therapeutics (France) € 2 million funding round Seventure Partners (France) - SODIV (France) - AIRFI (Alsace Inter Regio Fonds d’Investissement) (France) - IP Growth - Auriga Partners (France) - Sam Eletr, the Chairman of the Board Fundraising
2012-07-10 Hemarina (France) €6.3 million series B financing round Inserm Transfert Initiative (France)
Finistère Angels (France)
Armor Angels (France)
XMP (France)
Arkéa Capital Investissement (France)
a family office represented and mandated by Maurice Lesaffre
Transplantation - Technology - Services Fundraising